skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Immunotherapies are one of the fastest growing treatment algorithms in pharma at the moment, and non-small cell lung cancer (NSCLC) is just one area of oncology that is going to make the transition into being dominated by this type of therapy. Not only that, but this focus will help to triple the value of the NSCLC market by 2023.

Our newest infographic will allow you to explore the key events up to 2023 that will make immunotherapies a key treatment type in NSCLC, and the key players in this field.

What will you learn from this infographic?


  • How PD-1/PD-L1 inhibitors is forecast to overtake EGFR inhibitors as the most commercially successful treatment type in NSCLC


  • Which of the five PD-1/PD-L1 inhibitors set to launch by 2023 is forecast to lead the ways in sales and why?


  • The key launch dates of immunotherapies over the next four years you’ll need to look out for





Download now





電話:+81 (0)3 6273 4260